真实存在还是主观认知：高钾血症是心力衰竭中肾素 - 血管紧张素 - 醛固酮系统抑制的主要阻碍因素。 - Suppr

Suppr

超能文献

Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure.

作者信息

McCullough Peter A, Rangaswami Janani

机构信息

Baylor University Medical Center, Dallas, Texas, USA.

Baylor Heart and Vascular Institute, Dallas, Texas, USA.

出版信息

Nephron. 2018;138(3):173-175. doi: 10.1159/000485645. Epub 2017 Dec 5.

DOI:10.1159/000485645

PMID:29207385

Abstract

摘要

相似文献

Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure.真实存在还是主观认知：高钾血症是心力衰竭中肾素 - 血管紧张素 - 醛固酮系统抑制的主要阻碍因素。

Nephron. 2018;138(3):173-175. doi: 10.1159/000485645. Epub 2017 Dec 5.

Hyperkalemia Associated with Renin-Angiotensin-Aldosterone System Inhibition in Patients with Heart Failure; Underexplored and Overrated?心力衰竭患者中与肾素-血管紧张素-醛固酮系统抑制相关的高钾血症；未被充分研究还是被高估了？

Nephron. 2018;138(3):220-221. doi: 10.1159/000484990. Epub 2017 Nov 24.

Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.急性心力衰竭住院期间高钾血症与肾素-血管紧张素-醛固酮系统抑制剂治疗及其与死亡率的关系。

JACC Heart Fail. 2019 Nov;7(11):970-979. doi: 10.1016/j.jchf.2019.07.010. Epub 2019 Oct 9.

Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction.高钾血症和肾功能恶化对射血分数降低的慢性心力衰竭患者使用肾素-血管紧张素-醛固酮系统抑制剂的影响。

Clin Pharmacol Ther. 2017 Sep;102(3):389-391. doi: 10.1002/cpt.746. Epub 2017 Jul 14.

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.使用培多美索治疗可降低慢性肾脏病和肾素-血管紧张素系统抑制剂治疗高钾血症患者的醛固酮水平。

Kidney Int. 2016 Sep;90(3):696-704. doi: 10.1016/j.kint.2016.04.019. Epub 2016 Jun 24.

Treatment of Hyperkalemia in Heart Failure.心力衰竭患者高钾血症的治疗

Curr Heart Fail Rep. 2017 Aug;14(4):266-274. doi: 10.1007/s11897-017-0341-0.

[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].高钾血症作为限制使用阻断肾素-血管紧张素-醛固酮系统（RAAS）药物的一个因素

G Ital Nefrol. 2018 May;35(3).

Mineralcorticoid Receptor Antagonist Withdrawal for Hyperkalemia and Mortality in Patients with Heart Failure.醛固酮受体拮抗剂停药治疗心力衰竭伴高钾血症和死亡的效果。

Cardiorenal Med. 2020;10(3):145-153. doi: 10.1159/000505286. Epub 2020 Jan 24.

Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.在真实世界人群中，肾素-血管紧张素-醛固酮系统抑制剂致高钾血症的风险及与治疗中断相关的因素。

Nephrol Dial Transplant. 2021 Apr 26;36(5):826-839. doi: 10.1093/ndt/gfz263.

How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?面对心肾综合征时，我们应如何调整推荐的肾素-血管紧张素-醛固酮系统抑制治疗？

Circ Heart Fail. 2014 May;7(3):536. doi: 10.1161/CIRCHEARTFAILURE.113.000843.

引用本文的文献

Inpatient hospitalisation and mortality rate trends from 2004 to 2014 in the USA: a propensity score-matched case-control study of hyperkalaemia.2004 年至 2014 年美国住院患者住院率和死亡率趋势：高钾血症倾向评分匹配病例对照研究。

BMJ Open. 2022 May 19;12(5):e059324. doi: 10.1136/bmjopen-2021-059324.

RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study.慢性肾脏病患者肾素-血管紧张素-醛固酮系统抑制剂处方与高钾血症事件：一项单中心回顾性研究

Front Cardiovasc Med. 2022 Feb 11;9:824095. doi: 10.3389/fcvm.2022.824095. eCollection 2022.

Cardionephrology from the point of view of the cardiologist: no more agree to disagree-getting to 'yes' for every patient.心脏病专家视角下的心脏肾脏病学：不再各执一词——为每位患者达成共识。

Clin Kidney J. 2021 May 18;14(9):1995-1999. doi: 10.1093/ckj/sfab092. eCollection 2021 Sep.

Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.高钾血症的流行情况、临床影响和成本：特别关注心力衰竭。

Eur J Clin Invest. 2021 Aug;51(8):e13551. doi: 10.1111/eci.13551. Epub 2021 Mar 31.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验